ATAI Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$8.10median target· current $7.35 (+10.2%)14 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-2.79-96.8% YoY
Profit margin0.0%HEALTHCARE
Market cap$2.72BMid cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 15.43
- P/S (TTM)
- 608.71
- EV/EBITDA
- 0.27
Profitability & growth
- ROE (TTM)
- -417.2%
- Operating margin
- -2590.0%
- Revenue growth YoY
- 137.0%
- Dividend yield
- —
- Beta
- 1.55
Last earnings
Aug 11, 2026 · Estimate $-0.10 · Reported $-0.09
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About ATAI Life Sciences BV
Company profileATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 250 WEST 34TH STREET, NEW YORK, NY
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$2.72B
Shares outstanding$370.9M
52W high$7.45
52W low$3.27
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent